- Topic
8k Popularity
12k Popularity
11k Popularity
5k Popularity
2k Popularity
- Pin
- Gate July 2025 Transparency Report:
Accelerating Leadership in the Global Crypto Landscape!
#GateTransparencyReport# - 📢 Gate Square Exclusive: #PUBLIC Creative Contest# Is Now Live!
Join Gate Launchpool Round 297 — PublicAI (PUBLIC) and share your post on Gate Square for a chance to win from a 4,000 $PUBLIC prize pool
🎨 Event Period
Aug 18, 2025, 10:00 – Aug 22, 2025, 16:00 (UTC)
📌 How to Participate
Post original content on Gate Square related to PublicAI (PUBLIC) or the ongoing Launchpool event
Content must be at least 100 words (analysis, tutorials, creative graphics, reviews, etc.)
Add hashtag: #PUBLIC Creative Contest#
Include screenshots of your Launchpool participation (e.g., staking record, reward - 🎉 Hey Gate Square friends! Non-stop perks and endless excitement—our hottest posting reward events are ongoing now! The more you post, the more you win. Don’t miss your exclusive goodies! 🚀
🆘 #Gate 2025 Semi-Year Community Gala# | Square Content Creator TOP 10
Only 1 day left! Your favorite creator is one vote away from TOP 10. Interact on Square to earn Votes—boost them and enter the prize draw. Prizes: iPhone 16 Pro Max, Golden Bull sculpture, Futures Vouchers!
Details 👉 https://www.gate.com/activities/community-vote
1️⃣ #Show My Alpha Points# | Share your Alpha points & gains
Post your - 💙 Gate Square #Gate Blue Challenge# 💙
Show your limitless creativity with Gate Blue!
📅 Event Period
August 11 – 20, 2025
🎯 How to Participate
1. Post your original creation (image / video / hand-drawn art / digital work, etc.) on Gate Square, incorporating Gate’s brand blue or the Gate logo.
2. Include the hashtag #Gate Blue Challenge# in your post title or content.
3. Add a short blessing or message for Gate in your content (e.g., “Wishing Gate Exchange continued success — may the blue shine forever!”).
4. Submissions must be original and comply with community guidelines. Plagiarism or re
AstraZeneca claims that an oral lipid-lowering drug can drop bad cholesterol by more than 50%.
Jin10 data reported on April 2, that AstraZeneca (AZN.O) presented clinical data on a new lipid-lowering drug under investigation at the American College of Cardiology Annual Scientific Session held in Chicago. The interim trial data shows that a PCSK9 (proprotein convertase subtilisin/kexin type 9) oral lipid-lowering drug being developed by the company can reduce "bad cholesterol" by nearly 51%. AstraZeneca stated that patients taking this oral lipid-lowering drug once daily in addition to standard statin therapy can lower their low-density lipoprotein (LDL) cholesterol levels by nearly 51% after 12 weeks. LDL, also known as "bad cholesterol," is a major driver of cardiovascular events such as heart attacks and strokes.